Related Experiment Video
Updated: Oct 13, 2026
Establishment and Characterization of UTI and CAUTI in a Mouse Model
Published on: June 23, 2015
Evaluation of temafloxacin in a rat model of intra-abdominal abscess
H Thadepalli1, M Hajji, V K Perumal
1Department of Medicine and Pathology, Drew University School of Medicine and Science, Los Angeles, California.
Abstract:
The in-vitro activity of temafloxacin, a new fluoroquinolone, was evaluated in an experimental model of intra-abdominal abscess in rats. Mixed aerobic-anaerobic infection was induced by intraperitoneal implantation of gelatin capsules containing Bacteroides fragilis, Escherichia coli, and sterile rat faeces. Temafloxacin was highly active with a 90.9% cure rate in comparison with no treatment (no cures; P less than 0.0001), and as active as a combination of clindamycin and gentamicin (100% cure rate; P greater than 0.05). Temafloxacin (12 mg/dose) gave rise to serum concentrations that exceeded the MIC values of both microorganisms for at least 8 h.
Insights
Temafloxacin demonstrated high efficacy in treating experimental intra-abdominal abscesses in rats, achieving a 90.9% cure rate. This new fluoroquinolone showed comparable effectiveness to clindamycin and gentamicin combination therapy.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Intra-abdominal infections often involve polymicrobial infections, necessitating broad-spectrum antimicrobial agents.
- Fluoroquinolones represent a class of antibiotics with broad-spectrum activity against various bacterial pathogens.
Purpose of the Study:
- To evaluate the in vitro and in vivo efficacy of temafloxacin, a novel fluoroquinolone, against a polymicrobial intra-abdominal abscess model in rats.
- To compare the therapeutic effect of temafloxacin with a combination of clindamycin and gentamicin and untreated controls.
Main Methods:
- An experimental intra-abdominal abscess model was established in rats by intraperitoneal implantation of gelatin capsules containing a mixture of Bacteroides fragilis, Escherichia coli, and sterile rat feces.
- Animals were treated with temafloxacin, a combination of clindamycin and gentamicin, or received no treatment.
- Bacteriological and clinical outcomes, including cure rates, were assessed. Serum concentrations of temafloxacin were measured to determine pharmacokinetic parameters.
Main Results:
- Temafloxacin exhibited significant activity, resulting in a 90.9% cure rate in the intra-abdominal abscess model.
- This cure rate was statistically superior to the no-treatment group (P < 0.0001).
- Temafloxacin demonstrated comparable efficacy to the combination of clindamycin and gentamicin, which achieved a 100% cure rate (P > 0.05).
- A dose of 12 mg/kg of temafloxacin produced serum concentrations that exceeded the minimum inhibitory concentrations (MICs) for both B. fragilis and E. coli for at least 8 hours.
Conclusions:
- Temafloxacin is a highly effective antimicrobial agent for treating experimental intra-abdominal abscesses caused by mixed aerobic-anaerobic bacteria.
- The efficacy of temafloxacin in this model supports its potential as a therapeutic option for serious bacterial infections.
- Pharmacokinetic data suggest that temafloxacin achieves sustained therapeutic concentrations, contributing to its observed in vivo activity.
